COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA

作者
Lan Gao,Fei-Li Zhao,Shu‐Chuen Li
出处
期刊:International Journal of Technology Assessment in Health Care [Cambridge University Press]
卷期号:28 (4): 436-444 被引量:33
标识
DOI:10.1017/s0266462312000608
摘要

OBJECTIVES: The aim of this study was to evaluate the long-term cost-utility of liraglutide versus glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM), based on the results of clinical trial conducted in Asian population. METHODS: The validated UKPDS Outcomes Model was used to project life expectancy, quality adjusted life-years (QALYs), incidence of diabetes-related complication and cost of complications in patients receiving those regimens. Baseline cohort characteristics and treatment effects were derived from an Asian study. China-specific complication costs and utility score were taken from local studies. Patients' outcomes were modeled for 30 years and incremental cost-effectiveness ratios were calculated for liraglutide compared with glimepiride from the healthcare system perspective. Both future costs and clinical benefits were discounted at 3 percent. Sensitivity analyses were performed. RESULTS: Over a period of 30 years, compared with glimepiride, liraglutide 1.8 mg was associated with improvements in life expectancy (0.1 year) and quality adjusted life-year (0.168 QALY), and a reduced incidence of diabetes-related complications leading to an incremental cost-effectiveness ratio per QALY gained versus glimepiride of CNY 25,6871 (DEC 2010, 1 USD = 6.6227 CNY). CONCLUSIONS: Long-term projections indicated that liraglutide was associated with increased life expectancy, QALYs, and reduced complication incidences comparing with glimepiride. When the UK cost of liraglutide was discounted by 38 percent, liraglutide would be a cost-effective option in China from the healthcare system perspective using the 3X GDP/capita per QALY as the WTP threshold.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
林洁佳发布了新的文献求助10
刚刚
KanmenRider完成签到,获得积分10
刚刚
1秒前
W1ndyKnight发布了新的文献求助10
2秒前
每每反完成签到,获得积分0
2秒前
无私的泥猴桃完成签到 ,获得积分10
2秒前
勤恳的飞阳完成签到 ,获得积分10
3秒前
典雅的羿发布了新的文献求助10
3秒前
aaa完成签到,获得积分10
3秒前
lsq108发布了新的文献求助10
3秒前
沉默问夏完成签到,获得积分10
4秒前
4秒前
4秒前
Zxx发布了新的文献求助10
5秒前
落后的孤云完成签到,获得积分10
6秒前
彭于晏的应助被吴xl采纳,获得10
7秒前
lilili发布了新的文献求助10
7秒前
8秒前
8秒前
坚强的碧凡完成签到,获得积分10
8秒前
111发布了新的文献求助10
8秒前
8秒前
10秒前
小暴发布了新的文献求助10
11秒前
共享精神的应助被科研通管家采纳,获得10
12秒前
SciGPT的应助被科研通管家采纳,获得10
12秒前
慕青的应助被科研通管家采纳,获得10
12秒前
NexusExplorer的应助被科研通管家采纳,获得10
12秒前
orixero的应助被科研通管家采纳,获得10
12秒前
顺利的小甜瓜完成签到,获得积分10
12秒前
完美世界的应助被科研通管家采纳,获得10
12秒前
ding的应助被科研通管家采纳,获得10
12秒前
molihuakai的应助被科研通管家采纳,获得10
13秒前
852的应助被科研通管家采纳,获得10
13秒前
华仔的应助被科研通管家采纳,获得10
13秒前
13秒前
13秒前
研友_8op0RL完成签到,获得积分10
13秒前
科目三的应助被科研通管家采纳,获得10
13秒前
小蘑菇的应助被科研通管家采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186629
求助须知:如何正确求助?哪些是违规求助? 9574913
关于积分的说明 21838832
捐赠科研通 7784206
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559183
邀请新用户注册赠送积分活动 2481582